Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Niraparib significantly improves outcomes for ovarian cancer patients

ESMO 2016

7 - 11 Oct 2016

Published: 8 Oct 2016

Views: 2165

Rating:

Save

Dr Mansoor Raza Mirza - Rigshospitalet, Copenhagen University Hospital, Denmark

Dr Mirza speaks to ecancer at ESMO 2016 about results from the NOVA trial of niraparib, a PARP inhibitor, to treat platinum sensitive recurrent ovarian cancer.

Dr Mirza describes the significant extension of progression free survival in all patient subgroups assessed through the trial, hailing it as a 'break through'.

The results were published simultaneously to the conference in the New England Journal of Medicine.

Video of the press conference is available here.

Related Videos

Choosing Wisely in radiology Tanzania

Dr Revelian Iramu - Ocean Road Cancer Institute, Dar es Salaam, Tanzania

Choosing Wisely in radiology Tanzania ( Dr Revelian Iramu - Ocean Road Cancer Institute, Dar es Salaam, Tanzania )

TARGeted IORT INTRABEAM is a useful treatment option for early stage breast...

Dr Elena Sperk - Universitätsmedizin Mannheim, Mannheim, German

TARGeted IORT INTRABEAM is a useful treatment option for early stage breast cancer ( Dr Elena Sperk - Universitätsmedizin Mannheim, Mannheim, German )

Tusamitamab ravtansine combined with SoC shows encouraging anti-tumour activity...

Dr Luis Paz-Ares - Hospital Universitario 12 de Octubre, Madrid, Spain

Tusamitamab ravtansine combined with SoC shows encouraging anti-tumour activity for patients with nonsquamous NSCLC ( Dr Luis Paz-Ares - Hospital Universitario 12 de Octubre, Madrid, Spain )

CheckMate 649 biomarker analyses of NIVO + IPI vs chemo for patients with GC...

Dr Yelena Janjigian - Memorial Sloan Kettering Center, New York, USA

CheckMate 649 biomarker analyses of NIVO + IPI vs chemo for patients with GC/GEJC/EAC ( Dr Yelena Janjigian - Memorial Sloan Kettering Center, New York, USA )

Initial results from a phase 1 dose escalation trial of E-602 shows efficacy in...

Dr Jason Luke - University of Pittsburgh, Pittsburgh, USA

Initial results from a phase 1 dose escalation trial of E-602 shows efficacy in solid tumours ( Dr Jason Luke - University of Pittsburgh, Pittsburgh, USA )

Combination of camonsertib plus PARPi shows clinical activity in DDR-aberrant...

Dr Timothy Yap - The University of Texas MD Anderson Cancer Center, Houston, USA

Combination of camonsertib plus PARPi shows clinical activity in DDR-aberrant tumours ( Dr Timothy Yap - The University of Texas MD Anderson Cancer Center, Houston, USA )

ASCO GU 2023: Latest updates in mRCC

Dr Javier Puente, Dr Bernard Escudier, Prof Stéphane Oudard, Prof Viktor...

ASCO GU 2023: Latest updates in mRCC ( Dr Javier Puente, Dr Bernard Escudier, Prof Stéphane Oudard, Prof Viktor Grünwald and Prof Toni Choueiri )

Molecular profiling in prostate cancer: key challenges for clinical...

Dr Joaquin Mateo - Vall d’Hebron Institute of Oncology, Barcelona, Spain

Molecular profiling in prostate cancer: key challenges for clinical implementation ( Dr Joaquin Mateo - Vall d’Hebron Institute of Oncology, Barcelona, Spain )

Pembrolizumab with chemoradiation therapy vs placebo plus CRT for locally...

Prof Jean-Pascal Machiels - Cliniques Universitaires Sain-Luc, Brussels, Belgium

Pembrolizumab with chemoradiation therapy vs placebo plus CRT for locally advanced head and neck squamous cell carcinoma ( Prof Jean-Pascal Machiels - Cliniques Universitaires Sain-Luc, Brussels, Belgium )

More from ecancer